Replimune Group (HAM:7R8) Tariff Resilience Score: 8/10 (As of Aug. 13, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HAM:7R8 Replimune Group Inc HAM:7R8
19 GF Score
Price €11.49
! 4 Warning Signs
View Full Analysis

What is Replimune Group Tariff Resilience Score?

Replimune Group HAM:7R8 -0.73% 19 Tariff Resilience Score is 8 as of Aug. 13, 2026. GuruFocus rates HAM:7R8 with a GF Score™ of 19/100. The stock has 4 warning signs investors should review. Among 1,362 Biotechnology companies, Replimune Group ranks better than 98.68% on this metric.

Replimune Group has the Tariff Resilience Score of 8, which implies that the company might have Highly Resilient.

Replimune Group has Replimune Group Inc, a biotech firm, benefits from industry-specific tariff exemptions. Its supply chain is global but focused on specialized components with limited tariff exposure. The company has strong pricing power due to its innovative products.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Replimune Group might have Highly Resilient.

Replimune Group  (HAM:7R8) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Replimune Group Tariff Resilience Score Related Terms

HAM:7R8 vs ANNX, SLDB, ABUS: Tariff Resilience Score Comparison

For the Biotechnology subindustry, Replimune Group's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Replimune Group Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Replimune Group's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Replimune Group's Tariff Resilience Score falls into.


HAM:7R8
19GF Score
Replimune Group Inc HAM:7R8
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 8 mean?
Replimune Group (HAM:7R8) has a Tariff Resilience Score of 8 as of Aug. 13, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Replimune Group ranks #18 out of 1362 companies in the Biotechnology industry, placing it in the top 1.3%.
Is Replimune Group's Tariff Resilience Score too high?
Replimune Group's current Tariff Resilience Score is 8. The Biotechnology industry median Tariff Resilience Score is 4.00. Replimune Group's value of 8 is 100% above this industry median. Based on the distribution chart, Replimune Group ranks #18 out of 1362 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Replimune Group has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does Replimune Group's Tariff Resilience Score compare to ANNX and SLDB?
According to the Biotechnology industry distribution chart, Replimune Group ranks #18 out of 1362 companies for Tariff Resilience Score. This places Replimune Group in the top 1% of its industry — outperforming the majority of peers. The industry median Tariff Resilience Score is 4.00. Replimune Group's value of 8 is 100% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,362 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Replimune Group's current Tariff Resilience Score of 8 is 100% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Replimune Group's current Tariff Resilience Score is 8. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Replimune Group stock overvalued right now?
Replimune Group (HAM:7R8) has a current Tariff Resilience Score of 8. The current Tariff Resilience Score is 8 and 100% above the Biotechnology industry median of 4.00. Replimune Group's overall GF Score™ is 19/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Replimune Group (HAM:7R8), the current Tariff Resilience Score is 8 as of Aug. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Replimune Group Business Description

Other Exchanges REPL:USA7R8:Germany
Address 500 Unicorn Park Drive, Suite 303, 3rd Floor, Woburn, MA, USA, 01801
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.
19GF Score

Get the complete analysis for HAM:7R8

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€11.49
Price